Furthermore, glucagon-like peptide-1 receptor agonists(GLP1-RAs) and sodium–glucose cotransporter-2 inhibitors (SGLT-2is) haveeffectively reduced cardiovascular events in patients with DM [59, 60].Additionally, therapies targeting the proinflammatory and prothrombotic states inpatients with DM, such as low-dose rivaroxaban and colchicine, have provenbeneficial [61, 62]. The gene discussed is GLP1R; the disease is diabetes mellitus.